Effectiveness and Cost-Effectiveness Analysis of Influenza Vaccination Among the Adolescents in the United States
Abstract
reduce the heavy disease burden in every flu season. In this study, we applied a simulation model to estimate the economic outcomes of influenza vaccination among adolescents in the United States in 2024. In this study, we use the competing choice method to compare the costeffectiveness of vaccination and no vaccination. We divide the cohort group into the younger age group (10-14) and the elder age group (15-
19). We use the estimation of net cost and net quality-adjusted life years (QALYs) to calculate the incremental cost-effectiveness ratios (ICER)
of influenza vaccination in three different coverage of 50%, 80%, and 100% in 2024. The result shows the highest cost-effectiveness for 80%
coverage and younger age group, and the largest health benefit for 100% coverage among adolescents from 10 to 19 in the US in 2024.
Keywords
Full Text:
PDFReferences
[1] Babazadeh, A. et al. (2019) Influenza vaccination and Guillainbarr syndrome: Reality or fear, Journal of Translational Internal
Medicine, 7(4), pp. 137142. doi:10. 2478/jtim-2019-0028.
[2] Buchy, P. and Badur, S. (2020) Who and when to vaccinate against influenza, International Journal of Infectious Diseases, 93, pp.
375387. doi:10. 1016/j. ijid. 2020. 02. 040.
[3] Cheng, Y. et al. (2020) Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality,
Ageing Research Reviews, 62, p. 101124. doi:10. 1016/j. arr. 2020. 101124.
[4] FASTSTATS - Influenza (2023) Centers for Disease Control and Prevention. Available at: https://www. cdc. gov/nchs/fastats/flu. htm
(Accessed: 30 January 2024).
[5] Kim DeLuca, E. et al. (2023) Cost-effectiveness of routine annual influenza vaccination by age and risk status, Vaccine, 41(29), pp.
42394248. doi:10. 1016/j. vaccine. 2023. 04. 069.
[6] NHIS - Summary Health Statistics - Children (2018) Centers for Disease Control and Prevention. Available at: https://www. cdc. gov/
nchs/nhis/KIDS/www/index. htm (Accessed: 30 January 2024).
[7] Osterholm, M. T. et al. (2012) Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis, The Lancet
Infectious Diseases, 12(1), pp. 3644. doi:10. 1016/s1473-3099(11)70295-x.
[8] Peasah, S. K. et al. (2013) Influenza cost and cost-effectiveness studies globally A Review, Vaccine, 31(46), pp. 53395348. doi:10.
1016/j. vaccine. 2013. 09. 013.
[9] Pelton, S. I. , Mould-Quevedo, J. F. and Nguyen, V. H. (2023) Modelling the population-level benefits and cost-effectiveness of cellbased quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US, Expert Review of Vaccines,
23(1), pp. 8287. doi:10. 1080/14760584. 2023. 2295014.
[10] Prosser, L. A. et al. (2006) Health benefits, risks, and cost-effectiveness of influenza vaccination of children, Emerging Infectious Diseases, 12(10), pp. 15481558. doi:10. 3201/eid1210. 051015.
[11] Schiller, J. S. and Norris, T. (2023) Early Release of Selected Estimates Based on Data From the 2022 National Health Interview Survey, U. S. Department of Health and Human Services, Centers for Diseases Control and Prevention(National Center for Health Statistics), pp. 12.
[12] Smith, K. J. et al. (2016) Cost effectiveness of influenza vaccine choices in children aged 28 years in the U. S. , American Journal of
Preventive Medicine, 50(5), pp. 600608. doi:10. 1016/j. amepre. 2015. 12. 010.
[13] Stratton, K. R. (2012) Adverse effects of vaccines evidence and causality. Washington, D. C. : National Academies Press.
[14] Wang, Q. et al. (2023) Cost-effectiveness of seasonal influenza vaccination of children in China: A modeling analysis, Infectious Diseases of Poverty, 12(1). doi:10. 1186/s40249-023-01144-6.
Refbacks
- There are currently no refbacks.
